

1 POMERANTZ LLP
Jennifer Pafiti (SBN 282790)
2 1100 Glendon Avenue, 15th Floor
Los Angeles, California 90024
3 Telephone: (310) 405-7190
4 jpfafiti@pomlaw.com

5 *Attorney for Plaintiff*

6 *[Additional Counsel on Signature Page]*
7

8 UNITED STATES DISTRICT COURT
9 NORTHERN DISTRICT OF CALIFORNIA

10 RONALD A. SCHOEN, Individually and on
11 Behalf of All Others Similarly Situated,

12 Plaintiff,

13 v.

14 EIGER BIOPHARMACEUTICALS, INC.,
15 DAVID A. CORY, and SRIRAM RYALI,

16 Defendants.
17

Case No.

CLASS ACTION

COMPLAINT FOR VIOLATIONS OF THE
FEDERAL SECURITIES LAWS

DEMAND FOR JURY TRIAL

18 Plaintiff Ronald A. Schoen (“Plaintiff”), individually and on behalf of all others similarly
19 situated, by Plaintiff’s undersigned attorneys, for Plaintiff’s complaint against Defendants, alleges
20 the following based upon personal knowledge as to Plaintiff and Plaintiff’s own acts, and
21 information and belief as to all other matters, based upon, *inter alia*, the investigation conducted
22 by and through Plaintiff’s attorneys, which included, among other things, a review of the
23 Defendants’ public documents, conference calls and announcements made by Defendants, United
24 States (“U.S.”) Securities and Exchange Commission (“SEC”) filings, wire and press releases
25 published by and regarding Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”), analysts’
26 reports and advisories about the Company, and information readily obtainable on the Internet.
27
28

1 Plaintiff believes that substantial, additional evidentiary support will exist for the allegations set
2 forth herein after a reasonable opportunity for discovery.

3 **NATURE OF THE ACTION**

4 1. This is a federal securities class action on behalf of a class consisting of all persons
5 and entities other than Defendants that purchased or otherwise acquired Eiger securities between
6 March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”), seeking to recover
7 damages caused by Defendants’ violations of the federal securities laws and to pursue remedies
8 under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and
9 Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
10

11 2. Eiger is a commercial-stage biopharmaceutical company that focuses on the
12 development and commercialization of targeted therapies for rare and ultra-rare diseases.
13

14 3. Eiger’s product candidates include, among others, peginterferon lambda.
15 Peginterferon lambda is being evaluated for, *inter alia*, the treatment of COVID-19 in the
16 *TOGETHER* study, which is an independent multi-center, investigator-sponsored, randomized,
17 placebo-controlled adaptive platform Phase 3 study evaluating multiple therapeutics in newly
18 diagnosed, high-risk, non-hospitalized patients with mild-to-moderate COVID-19. Peginterferon
19 lambda was added to the *TOGETHER* study in May 2021.
20

21 4. In March 2022, based on the results of the *TOGETHER* study, Eiger announced
22 that it would submit an Emergency Use Authorization (“EUA”) request to the U.S. Food and Drug
23 Administration (“FDA”) for peginterferon lambda for the treatment of patients with mild-to-
24 moderate COVID-19 (the “peginterferon lambda EUA”).

25 5. Throughout the Class Period, Defendants made materially false and misleading
26 statements regarding the Company’s business, operations, and compliance policies. Specifically,
27 Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants
28

1 overstated Eiger’s clinical and regulatory drug development expertise; (ii) Defendants failed to
2 properly assess, and/or ignored issues with, the design of the *TOGETHER* study and its ability to
3 support the peginterferon lambda EUA; (iii) there were issues with the conduct of the *TOGETHER*
4 study and/or the *TOGETHER* study was not properly designed for the peginterferon lambda EUA
5 in the current context of the pandemic; (iv) as a result, the FDA was unlikely to approve the
6 submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon
7 lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated;
8 and (vi) as a result, the Company’s public statements were materially false and misleading at all
9 relevant times.
10

11 6. On September 6, 2022, Eiger issued a press release “provid[ing] an update on the
12 status of its planned request for [EUA] of peginterferon lambda for the treatment of patients with
13 mild-to-moderate COVID-19 based on its most recent communications with the
14 [FDA].” Specifically, the Company announced that “[f]ollowing a cooperative and extensive pre-
15 EUA information exchange with [the] FDA regarding the Phase 3 *TOGETHER* study of
16 peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine
17 whether the criteria for the submission of an application and issuance of an EUA are likely to be
18 met.”
19

20 7. On this news, Eiger’s stock price fell \$2.51 per share, or 29.36%, to close at \$6.04
21 per share on September 6, 2022.
22

23 8. Then, on October 5, 2022, Eiger announced that it would not seek an EUA request
24 for peginterferon lambda after the FDA had “denied the request for a pre-EUA meeting.”
25 Specifically, the Company disclosed that, “[c]iting its concerns about the conduct of the
26 *TOGETHER* study, [the] FDA concluded that any authorization request based on the[] data
27
28

1 [presented] is unlikely to meet the statutory criteria for issuance of an EUA in the current context
2 of the pandemic.”

3 9. On this news, Eiger’s stock price fell \$0.37 per share, or 5.01%, to close at \$7.02
4 per share on October 5, 2022.

5 10. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline
6 in the market value of the Company’s securities, Plaintiff and other Class members have suffered
7 significant losses and damages.
8

9 **JURISDICTION AND VENUE**

10 11. The claims asserted herein arise under and pursuant to Sections 10(b) and 20(a) of
11 the Exchange Act (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder by the
12 SEC (17 C.F.R. § 240.10b-5).
13

14 12. This Court has jurisdiction over the subject matter of this action pursuant to 28
15 U.S.C. § 1331 and Section 27 of the Exchange Act.

16 13. Venue is proper in this Judicial District pursuant to Section 27 of the Exchange Act
17 (15 U.S.C. § 78aa) and 28 U.S.C. § 1391(b). Eiger is headquartered in this Judicial District,
18 Defendants conduct business in this Judicial District, and a significant portion of Defendants’
19 activities took place within this Judicial District.
20

21 14. In connection with the acts alleged in this complaint, Defendants, directly or
22 indirectly, used the means and instrumentalities of interstate commerce, including, but not limited
23 to, the mails, interstate telephone communications, and the facilities of the national securities
24 markets.
25
26
27
28

PARTIES

1
2 15. Plaintiff, as set forth in the attached Certification, acquired Eiger securities at
3 artificially inflated prices during the Class Period and was damaged upon the revelation of the
4 alleged corrective disclosures.

5
6 16. Defendant Eiger is a Delaware corporation with principal executive offices located
7 at 2155 Park Boulevard, Palo Alto, California 94306. The Company’s common stock trades in an
8 efficient market on the Nasdaq Stock Market (“NASDAQ”) under the ticker symbol “EIGR”.

9 17. Defendant David A. Cory (“Cory”) has served as Eiger’s President and Chief
10 Executive Officer at all relevant times.

11 18. Defendant Sriram Ryali (“Ryali”) has served as Eiger’s Chief Financial Officer at
12 all relevant times.

13 19. Defendants Cory and Ryali are sometimes referred to herein as the “Individual
14 Defendants.”

15
16 20. The Individual Defendants possessed the power and authority to control the
17 contents of Eiger’s SEC filings, press releases, and other market communications. The Individual
18 Defendants were provided with copies of Eiger’s SEC filings and press releases alleged herein to
19 be misleading prior to or shortly after their issuance and had the ability and opportunity to prevent
20 their issuance or to cause them to be corrected. Because of their positions with Eiger, and their
21 access to material information available to them but not to the public, the Individual Defendants
22 knew that the adverse facts specified herein had not been disclosed to and were being concealed
23 from the public, and that the positive representations being made were then materially false and
24 misleading. The Individual Defendants are liable for the false statements and omissions pleaded
25 herein.
26
27
28

1 Exchange Act” and that “[t]he information contained in the [2020 10-K] fairly presents, in all
2 material respects, the financial condition and results of operations of the Company.”

3 25. On May 3, 2021, Eiger issued a press release announcing that peginterferon lambda
4 would be added to the *TOGETHER* study, stating, in relevant part:

5
6 *TOGETHER* is an ongoing, multi-center, investigator-sponsored, randomized,
7 placebo-controlled Phase 3 study evaluating multiple therapeutics in newly
8 diagnosed, non-hospitalized patients with COVID-19, and will now include an
9 investigational arm of Lambda as a single subcutaneous dose. The primary
10 endpoint is a clinical outcome comparing emergency room visits and/or
11 hospitalization in each active arm versus placebo. Each arm targets enrollment of
up to 800 patients at high risk for developing complications from progression of
COVID-19, with planned interim analyses for futility in each arm. The *TOGETHER*
platform study is currently recruiting at eleven sites in Brazil and may expand to
include a site in Toronto, Canada.

12 26. On May 6, 2021, Eiger issued a press release announcing its first quarter 2021
13 financial results and providing a business update, stating, among other things, that the *TOGETHER*
14 study’s “[e]ndpoints align with FDA Guidance for COVID-19 therapeutics[.]”

15 27. On August 5, 2021, Eiger issued a press release announcing its second quarter 2021
16 financial results and providing a business update, including, among other developments, that the
17 “Phase 3 *TOGETHER* study [is] enrolling patients across clinical sites in Brazil”; that Defendants
18 expect an “[i]nterim futility data analysis potentially by end of 2021”; and that “[p]ositive data
19 could support submission for emergency use authorization[.]”

20
21 28. On September 20, 2021, Eiger issued a press release “announc[ing] that the Data
22 Safety Monitoring Board (DSMB) recommended that investigators continue enrollment of the
23 Peginterferon Lambda arm in the Phase 3 *TOGETHER* platform study.” That press release further
24 stated, in relevant part:

25
26 The per protocol interim futility analysis was based on a sample size of 453 patients,
randomized 1:1 active treatment to placebo.

27
28 *TOGETHER* is a multi-center, investigator-sponsored, randomized, placebo-
controlled adaptive platform Phase 3 study evaluating therapeutics in newly

1 diagnosed, high-risk, non-hospitalized patients with COVID-19. The primary
2 endpoint is a clinical outcome comparing emergency setting visits and/or
3 hospitalization in each active arm versus placebo. The DSMB provides
4 independent oversight for the trial and has previously discontinued five other
5 therapeutics due to observed futility. The Peginterferon Lambda arm targets
6 enrollment of up to 800 patients at high risk for developing complications from
7 progression of COVID-19. The *TOGETHER* platform study is currently recruiting
8 at twelve sites in Brazil.

9
10 29. On March 10, 2022, Eiger issued a press release announcing its fourth quarter and
11 full year 2021 financial results and providing a business update, including, among other
12 developments, that peginterferon lambda showed “[n]ovel mechanism of action, agnostic to
13 variants and mutations”; that the “*TOGETHER* Phase 3 study [is] fully enrolled” and “[i]ncludes
14 unvaccinated and vaccinated patients across multiple variants”; and that “[t]opline data [is]
15 planned in March 2022[.]”

16
17 30. The same press release also quoted Defendant Cory, who stated that Defendants
18 “expect 2022 to be a transformational year for Eiger with topline data planned from” *inter alia*
19 “[t]he Phase 3 *TOGETHER* study of Peginterferon Lambda for COVID-19 [that] is expected to
20 readout later this month” and that Defendants “look forward to reporting results from th[is]
21 potentially registration enabling stud[y.]”

22
23 31. Also on March 10, 2022, Eiger filed an annual report on Form 10-K with the SEC,
24 reporting the Company’s financial and operational results for the quarter and year ended December
25 31, 2021 (the “2021 10-K”). With respect to the *TOGETHER* study’s evaluation of peginterferon
26 lambda as a treatment for COVID-19, that filing stated, in relevant part:

27
28 Lambda is currently in an investigator sponsored Phase 3, multi-center,
randomized, placebo-controlled adaptive platform study, called TOGETHER,
evaluating therapeutics in newly diagnosed, high-risk, non-hospitalized patients
with COVID-19 across twelve clinical trial sites in Brazil.

The primary endpoint compares the number of emergency setting visits,
hospitalizations, and/or deaths in treated patients versus placebo through Day 28.
TOGETHER has completed enrollment of over 1,800 patients at high risk for
developing complications from progression of COVID-19 randomized 1:1 lambda

1 vs. placebo. In December 2021, the Data Safety Monitoring Board (DSMB) has
2 conducted a second per protocol interim futility analysis on 1,003 patients and
3 recommended continuation of the study. Data from this study is expected in first
4 quarter 2022.

4 We have an open [Investigational New Drug Application] for lambda in COVID-
19. Pending positive results from the Phase 3 TOGETHER study, we plan to submit
5 an [EUA] request to the FDA this year.

6 32. The 2021 10-K also purported to warn investors that Defendants “may not receive
7 an [EUA] from [the] FDA for the use of lambda in COVID-19[.]” stating, in relevant part:

8 If we do not receive an EUA from [the] FDA, we will not be able to commercialize
9 lambda in COVID-19 and may be required to conduct additional clinical trials for
10 an EUA. Obtaining such an authorization is dependent upon a number of factors,
11 which are not under our control. For example, the TOGETHER study [is] an
12 investigator sponsored study conducted within a single country, Brazil. [The] FDA
may require a company-sponsored study with data from additional patient
populations.

13 Plainly, the foregoing risk warning was a generic, boilerplate provision that was not tailored to
14 Eiger’s actual known risks regarding issues with the conduct of the *TOGETHER* study. Moreover,
15 the foregoing risk warning downplayed the FDA’s likely refusal to accept the submission of a
16 peginterferon lambda EUA.

17 33. Appended as exhibits to the 2021 10-K were substantively the same SOX
18 certifications as referenced in ¶ 24 *supra*, signed by the Individual Defendants.

19 34. On March 17, 2022, Eiger issued a press release (the “March 2022 Press Release”)
20 announcing peginterferon lambda’s successful results in the *TOGETHER* study, stating, *inter alia*,
21 “that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related
22 hospitalizations or emergency room visits greater than six hours by 50% (primary endpoint) and
23 death by 60% in the Phase 3 *TOGETHER* study,” and that “Eiger plans to discuss the results with
24 FDA and submit an EUA as soon as possible.”

25 35. In addition, the March 2022 Press Release quoted Defendant Cory, who stated, in
26 relevant part:
27
28

1 These data demonstrate that a single subcutaneous injection of Lambda has the
2 potential to be a convenient, ‘one and done’ treatment to reduce the severity of
3 COVID-19, reducing hospitalizations and death – even in a vaccinated population
4 With the continued global impact of COVID-19, we are encouraged by this
5 data and look forward to supporting the global public health response [W]e
6 look forward to discussing these results with [the] FDA and submitting an EUA
7 application to add Lambda to the evolving armamentarium of COVID-19
8 therapeutics.

9 36. The March 2022 Press Release also touted the *TOGETHER* study itself, stating that
10 “[t]he Phase 3 *TOGETHER* study of Lambda is the second largest study to date of a COVID-19
11 therapeutic”; that “[f]inal analyses evaluated data from 1,936 patients, with 84% of patients having
12 received at least a single dose of any COVID-19 vaccine”; and that “[f]inal analyses us[ed] a
13 Bayesian analytic framework [that] showed[,]” among other things, that “Lambda [was] highly
14 superior compared to placebo on the primary endpoint, with a probability of superiority of 99.91%,
15 surpassing the prespecified superiority threshold of 97.6%[.]”

16 37. With further respect to how the *TOGETHER* study was conducted, the March 2022
17 Press Release stated, in relevant part:

18 Eligibility criteria required that all patients had laboratory-confirmed mild or
19 moderate COVID-19, and were randomized within 7 days of symptom onset. High-
20 risk criteria were defined by patients having at least one of the following, including
21 but not limited to: > age 50, diabetes, hypertension, CV disease, lung disease,
22 kidney disease, obesity, etc. The study enrolled patients regardless of vaccination
23 status or variant strain of SARS-CoV-2. The primary endpoint was a clinical
24 outcome comparing hospitalizations or emergency room visits greater than six
25 hours after a single subcutaneous injection of Lambda versus placebo. The DSMB
26 provided independent oversight for the trial and had previously discontinued other
27 therapeutics due to observed futility. The *TOGETHER* study recruited from twelve
28 sites in Brazil.

38. On May 5, 2022, Eiger issued a press release announcing its first quarter 2022
financial results and providing a business update. In addition to touting peginterferon lambda’s
results in the *TOGETHER* study, that press release represented, in relevant part, that Defendants
were “[a]ctively engaging with [the] FDA” on the peginterferon lambda EUA while preparing for

1 its submission, and that the “[g]ating component for [the] EUA application is full data analyses
2 from *TOGETHER* team which is in process and nearing completion[.]”

3 39. The same press release also quoted Defendant Cory, who stated, in relevant part,
4 that “[w]e are laser focused on executing our development and commercialization strategies and
5 anticipate significant value-creating milestones this quarter, including the submission of an [EUA]
6 application for lambda to treat COVID-19[.]”

7
8 40. On August 4, 2022, Eiger issued a press release announcing its second quarter 2022
9 financial results and providing a business update, including, among other developments, that
10 Defendants were “[a]ctively engaged with [the FDA] on [the] potential [EUA] application since
11 announcement of topline data in March 2022 and have provided responses to all of [the] FDA’s
12 information requests during this time[.]”

13
14 41. The statements referenced in ¶¶ 23-40 were materially false and misleading because
15 Defendants made false and/or misleading statements, as well as failed to disclose material adverse
16 facts about the Company’s business, operations, and compliance policies. Specifically,
17 Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants
18 overstated Eiger’s clinical and regulatory drug development expertise; (ii) Defendants failed to
19 properly assess, and/or ignored issues with, the design of the *TOGETHER* study and its ability to
20 support the peginterferon lambda EUA; (iii) there were issues with the conduct of the *TOGETHER*
21 study and/or the *TOGETHER* study was not properly designed for the peginterferon lambda EUA
22 in the current context of the pandemic; (iv) as a result, the FDA was unlikely to approve the
23 submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon
24 lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated;
25 and (vi) as a result, the Company’s public statements were materially false and misleading at all
26 relevant times.
27
28

The Truth Begins to Emerge

1
2 42. On September 6, 2022, during pre-market hours, Eiger issued a press release (the
3 “September 2022 Press Release”) “provid[ing] an update on the status of its planned request for
4 [EUA] of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19
5 based on its most recent communications with the [FDA].” Specifically, the September 2022 Press
6 Release stated, in relevant part, that “[f]ollowing a cooperative and extensive pre-EUA information
7 exchange with FDA regarding the Phase 3 *TOGETHER* study of peginterferon lambda for COVID-
8 19, the agency has indicated that it is not yet able to determine whether the criteria for the
9 submission of an application and issuance of an EUA are likely to be met.”

10
11 43. On this news, Eiger’s stock price fell \$2.51 per share, or 29.36%, to close at \$6.04
12 per share on September 6, 2022. Despite this decline in the Company’s stock price, Eiger securities
13 continued to trade at artificially inflated prices throughout the remainder of the Class Period
14 because of Defendants’ continued misstatements and omissions regarding the *TOGETHER* study
15 and peginterferon lambda’s regulatory and commercial prospects as a treatment for COVID-19.

16
17 44. For example, the September 2022 Press Release represented that “Eiger remains in
18 active dialogue with [the] FDA and will provide additional information to the agency that the
19 company believes could be supportive of an EUA.”

20
21 45. Likewise, the September 2022 Press Release advised investors that “[t]he company
22 has recently generated new data and analyses from the *TOGETHER* study that it plans to discuss
23 with FDA, including further statistical modeling and efficacy analyses of the study’s primary and
24 secondary endpoints in patients treated within three days of symptom onset”; that “[t]he endpoint
25 of hospitalization due to COVID-19 and all-cause mortality for patients treated within three days
26 of symptom onset is consistent with the endpoint used to authorize other therapeutics for
27 emergency use”; and that “Eiger plans to provide new additional analyses of long-term follow-up
28

1 data, including rates of rebound and incidence of long COVID, as well as an indirect comparative
2 analysis of mortality and hospitalizations in vaccinated patients when treated with peginterferon
3 lambda compared to other therapeutics authorized for emergency use.”

4 46. The September 2022 Press Release also quoted Defendant Cory, who assured
5 investors that Defendants “remain committed to continued engagement with the [FDA] to obtain
6 the necessary alignment to submit our EUA application for peginterferon lambda,” and that
7 “[g]iven its unique mechanism of action and the ongoing need for effective COVID-19
8 therapeutics, making peginterferon lambda available for patients remains a priority for Eiger.”

9 47. The statements referenced in ¶¶ 42-46 were materially false and misleading because
10 Defendants made false and/or misleading statements, as well as failed to disclose material adverse
11 facts about the Company’s business, operations, and compliance policies. Specifically,
12 Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants
13 overstated Eiger’s clinical and regulatory drug development expertise; (ii) Defendants failed to
14 properly assess, and/or ignored issues with, the design of the *TOGETHER* study and its ability to
15 support the peginterferon lambda EUA; (iii) there were issues with the conduct of the *TOGETHER*
16 study and/or the *TOGETHER* study was not properly designed for the peginterferon lambda EUA
17 in the current context of the pandemic; (iv) as a result, the FDA was unlikely to approve the
18 submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon
19 lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated;
20 and (vi) as a result, the Company’s public statements were materially false and misleading at all
21 relevant times.
22
23
24

25 **The Truth Fully Emerges**

26 48. On October 5, 2022, during pre-market hours, Eiger announced that it would not
27 seek an EUA application for peginterferon lambda, stating, in relevant part:
28

1 [F]ollowing feedback from the [FDA], the company will not submit an [EUA]
2 application of peginterferon lambda for the treatment of patients with mild-to-
3 moderate COVID-19.

4 Following Eiger’s press release on September 6, 2022, the company submitted a
5 pre-EUA meeting request to [the] FDA, as well as additional morbidity and
6 mortality outcomes data and analyses from the investigator-sponsored *TOGETHER*
7 study. This included further statistical modeling and efficacy analyses of the study’s
8 primary and secondary endpoints and long-term follow-up data that the company
9 believes continue to support the initial positive topline outcomes reported in March.
10 In response, [the] FDA denied the request for a pre-EUA meeting. ***Citing its
11 concerns about the conduct of the TOGETHER study, [the] FDA concluded that
12 any authorization request based on these data is unlikely to meet the statutory
13 criteria for issuance of an EUA in the current context of the pandemic.***

(Emphasis added.)

14 49. On this news, Eiger’s stock price fell \$0.37 per share, or 5.01%, to close at \$7.02
15 per share on October 5, 2022.

16 50. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline
17 in the market value of the Company’s securities, Plaintiff and other Class members have suffered
18 significant losses and damages.

19 PLAINTIFF’S CLASS ACTION ALLEGATIONS

20 51. Plaintiff brings this action as a class action pursuant to Federal Rule of Civil
21 Procedure 23(a) and (b)(3) on behalf of a Class, consisting of all those who purchased or otherwise
22 acquired Eiger securities during the Class Period (the “Class”); and were damaged upon the
23 revelation of the alleged corrective disclosures. Excluded from the Class are Defendants herein,
24 the officers and directors of the Company, at all relevant times, members of their immediate
25 families and their legal representatives, heirs, successors or assigns and any entity in which
26 Defendants have or had a controlling interest.

27 52. The members of the Class are so numerous that joinder of all members is
28 impracticable. Throughout the Class Period, Eiger securities were actively traded on the
NASDAQ. While the exact number of Class members is unknown to Plaintiff at this time and can

1 be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or
2 thousands of members in the proposed Class. Record owners and other members of the Class may
3 be identified from records maintained by Eiger or its transfer agent and may be notified of the
4 pendency of this action by mail, using the form of notice similar to that customarily used in
5 securities class actions.

6
7 53. Plaintiff's claims are typical of the claims of the members of the Class as all
8 members of the Class are similarly affected by Defendants' wrongful conduct in violation of
9 federal law that is complained of herein.

10 54. Plaintiff will fairly and adequately protect the interests of the members of the Class
11 and has retained counsel competent and experienced in class and securities litigation. Plaintiff has
12 no interests antagonistic to or in conflict with those of the Class.

13
14 55. Common questions of law and fact exist as to all members of the Class and
15 predominate over any questions solely affecting individual members of the Class. Among the
16 questions of law and fact common to the Class are:

- 17 • whether the federal securities laws were violated by Defendants' acts as alleged
18 herein;
- 19 • whether statements made by Defendants to the investing public during the Class
20 Period misrepresented material facts about the business, operations and
21 management of Eiger;
- 22 • whether the Individual Defendants caused Eiger to issue false and misleading
23 financial statements during the Class Period;
- 24 • whether Defendants acted knowingly or recklessly in issuing false and misleading
25 financial statements;
- 26 • whether the prices of Eiger securities during the Class Period were artificially
27 inflated because of the Defendants' conduct complained of herein; and
- 28 • whether the members of the Class have sustained damages and, if so, what is the
proper measure of damages.

1 56. A class action is superior to all other available methods for the fair and efficient
2 adjudication of this controversy since joinder of all members is impracticable. Furthermore, as the
3 damages suffered by individual Class members may be relatively small, the expense and burden
4 of individual litigation make it impossible for members of the Class to individually redress the
5 wrongs done to them. There will be no difficulty in the management of this action as a class action.
6

7 57. Plaintiff will rely, in part, upon the presumption of reliance established by the fraud-
8 on-the-market doctrine in that:

- 9 • Defendants made public misrepresentations or failed to disclose material facts
10 during the Class Period;
- 11 • the omissions and misrepresentations were material;
- 12 • Eiger securities are traded in an efficient market;
- 13 • the Company's shares were liquid and traded with moderate to heavy volume
14 during the Class Period;
- 15 • the Company traded on the NASDAQ and was covered by multiple analysts;
- 16 • the misrepresentations and omissions alleged would tend to induce a reasonable
17 investor to misjudge the value of the Company's securities; and
- 18 • Plaintiff and members of the Class purchased, acquired and/or sold Eiger
19 securities between the time the Defendants failed to disclose or misrepresented
20 material facts and the time the true facts were disclosed, without knowledge of
21 the omitted or misrepresented facts.

22 58. Based upon the foregoing, Plaintiff and the members of the Class are entitled to a
23 presumption of reliance upon the integrity of the market.

24 59. Alternatively, Plaintiff and the members of the Class are entitled to the presumption
25 of reliance established by the Supreme Court in *Affiliated Ute Citizens of the State of Utah v.*
26 *United States*, 406 U.S. 128, 92 S. Ct. 2430 (1972), as Defendants omitted material information in
27 their Class Period statements in violation of a duty to disclose such information, as detailed above.
28

COUNT I

(Violations of Section 10(b) of the Exchange Act and Rule 10b-5 Promulgated Thereunder Against All Defendants)

60. Plaintiff repeats and re-alleges each and every allegation contained above as if fully set forth herein.

61. This Count is asserted against Defendants and is based upon Section 10(b) of the Exchange Act, 15 U.S.C. § 78j(b), and Rule 10b-5 promulgated thereunder by the SEC.

62. During the Class Period, Defendants engaged in a plan, scheme, conspiracy and course of conduct, pursuant to which they knowingly or recklessly engaged in acts, transactions, practices and courses of business which operated as a fraud and deceit upon Plaintiff and the other members of the Class; made various untrue statements of material facts and omitted to state material facts necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; and employed devices, schemes and artifices to defraud in connection with the purchase and sale of securities. Such scheme was intended to, and, throughout the Class Period, did: (i) deceive the investing public, including Plaintiff and other Class members, as alleged herein; (ii) artificially inflate and maintain the market price of Eiger securities; and (iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Eiger securities and options at artificially inflated prices. In furtherance of this unlawful scheme, plan and course of conduct, Defendants, and each of them, took the actions set forth herein.

63. Pursuant to the above plan, scheme, conspiracy and course of conduct, each of the Defendants participated directly or indirectly in the preparation and/or issuance of the quarterly and annual reports, SEC filings, press releases and other statements and documents described above, including statements made to securities analysts and the media that were designed to influence the market for Eiger securities. Such reports, filings, releases and statements were

1 materially false and misleading in that they failed to disclose material adverse information and
2 misrepresented the truth about Eiger's finances and business prospects.

3 64. By virtue of their positions at Eiger, Defendants had actual knowledge of the
4 materially false and misleading statements and material omissions alleged herein and intended
5 thereby to deceive Plaintiff and the other members of the Class, or, in the alternative, Defendants
6 acted with reckless disregard for the truth in that they failed or refused to ascertain and disclose
7 such facts as would reveal the materially false and misleading nature of the statements made,
8 although such facts were readily available to Defendants. Said acts and omissions of Defendants
9 were committed willfully or with reckless disregard for the truth. In addition, each Defendant
10 knew or recklessly disregarded that material facts were being misrepresented or omitted as
11 described above.
12

13 65. Information showing that Defendants acted knowingly or with reckless disregard
14 for the truth is peculiarly within Defendants' knowledge and control. As the senior managers
15 and/or directors of Eiger, the Individual Defendants had knowledge of the details of Eiger's
16 internal affairs.
17

18 66. The Individual Defendants are liable both directly and indirectly for the wrongs
19 complained of herein. Because of their positions of control and authority, the Individual
20 Defendants were able to and did, directly or indirectly, control the content of the statements of
21 Eiger. As officers and/or directors of a publicly-held company, the Individual Defendants had a
22 duty to disseminate timely, accurate, and truthful information with respect to Eiger's businesses,
23 operations, future financial condition and future prospects. As a result of the dissemination of the
24 aforementioned false and misleading reports, releases and public statements, the market price of
25 Eiger securities was artificially inflated throughout the Class Period. In ignorance of the adverse
26 facts concerning Eiger's business and financial condition which were concealed by Defendants,
27
28

1 Plaintiff and the other members of the Class purchased or otherwise acquired Eiger securities at
2 artificially inflated prices and relied upon the price of the securities, the integrity of the market for
3 the securities and/or upon statements disseminated by Defendants, and were damaged thereby.

4 67. During the Class Period, Eiger securities were traded on an active and efficient
5 market. Plaintiff and the other members of the Class, relying on the materially false and misleading
6 statements described herein, which the Defendants made, issued or caused to be disseminated, or
7 relying upon the integrity of the market, purchased or otherwise acquired shares of Eiger securities
8 at prices artificially inflated by Defendants' wrongful conduct. Had Plaintiff and the other
9 members of the Class known the truth, they would not have purchased or otherwise acquired said
10 securities, or would not have purchased or otherwise acquired them at the inflated prices that were
11 paid. At the time of the purchases and/or acquisitions by Plaintiff and the Class, the true value of
12 Eiger securities were substantially lower than the prices paid by Plaintiff and the other members
13 of the Class. The market price of Eiger securities declined sharply upon public disclosure of the
14 facts alleged herein to the injury of Plaintiff and Class members.

15
16
17 68. By reason of the conduct alleged herein, Defendants knowingly or recklessly,
18 directly or indirectly, have violated Section 10(b) of the Exchange Act and Rule 10b-5
19 promulgated thereunder.

20
21 69. As a direct and proximate result of Defendants' wrongful conduct, Plaintiff and the
22 other members of the Class suffered damages in connection with their respective purchases,
23 acquisitions, and sales of the Company's securities during the Class Period, upon the disclosure
24 that the Company had been disseminating misrepresented financial statements to the investing
25 public.

COUNT II

(Violations of Section 20(a) of the Exchange Act Against the Individual Defendants)

1
2
3 70. Plaintiff repeats and re-alleges each and every allegation contained in the foregoing
4 paragraphs as if fully set forth herein.

5
6 71. During the Class Period, the Individual Defendants participated in the operation
7 and management of Eiger, and conducted and participated, directly and indirectly, in the conduct
8 of Eiger’s business affairs. Because of their senior positions, they knew the adverse non-public
9 information about Eiger’s misstatement of income and expenses and false financial statements.

10 72. As officers and/or directors of a publicly owned company, the Individual
11 Defendants had a duty to disseminate accurate and truthful information with respect to Eiger’s
12 financial condition and results of operations, and to correct promptly any public statements issued
13 by Eiger which had become materially false or misleading.

14
15 73. Because of their positions of control and authority as senior officers, the Individual
16 Defendants were able to, and did, control the contents of the various reports, press releases and
17 public filings which Eiger disseminated in the marketplace during the Class Period concerning
18 Eiger’s results of operations. Throughout the Class Period, the Individual Defendants exercised
19 their power and authority to cause Eiger to engage in the wrongful acts complained of herein. The
20 Individual Defendants, therefore, were “controlling persons” of Eiger within the meaning of
21 Section 20(a) of the Exchange Act. In this capacity, they participated in the unlawful conduct
22 alleged which artificially inflated the market price of Eiger securities.

23
24 74. Each of the Individual Defendants, therefore, acted as a controlling person of Eiger.
25 By reason of their senior management positions and/or being directors of Eiger, each of the
26 Individual Defendants had the power to direct the actions of, and exercised the same to cause,
27 Eiger to engage in the unlawful acts and conduct complained of herein. Each of the Individual
28

1 Defendants exercised control over the general operations of Eiger and possessed the power to
2 control the specific activities which comprise the primary violations about which Plaintiff and the
3 other members of the Class complain.

4 75. By reason of the above conduct, the Individual Defendants are liable pursuant to
5 Section 20(a) of the Exchange Act for the violations committed by Eiger.
6

7 **PRAYER FOR RELIEF**

8 **WHEREFORE**, Plaintiff demands judgment against Defendants as follows:

9 A. Determining that the instant action may be maintained as a class action under Rule
10 23 of the Federal Rules of Civil Procedure, and certifying Plaintiff as the Class representative;

11 B. Requiring Defendants to pay damages sustained by Plaintiff and the Class by reason
12 of the acts and transactions alleged herein;

13 C. Awarding Plaintiff and the other members of the Class prejudgment and post-
14 judgment interest, as well as their reasonable attorneys' fees, expert fees and other costs; and

15 D. Awarding such other and further relief as this Court may deem just and proper.
16

17 **DEMAND FOR TRIAL BY JURY**

18 Plaintiff hereby demands a trial by jury.

19 Dated: November 8, 2022

Respectfully submitted,

20 POMERANTZ LLP

21 /s/ Jennifer Pafiti

22 Jennifer Pafiti (SBN 282790)
23 1100 Glendon Avenue, 15th Floor
24 Los Angeles, California 90024
25 Telephone: (310) 405-7190
26 jpfafiti@pomlaw.com

27 POMERANTZ LLP
28 Jeremy A. Lieberman
(*pro hac vice* application forthcoming)
J. Alexander Hood II
(*pro hac vice* application forthcoming)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

600 Third Avenue, 20th Floor
New York, New York 10016
Telephone: (212) 661-1100
Facsimile: (917) 463-1044
jalieberman@pomlaw.com
ahood@pomlaw.com

Attorneys for Plaintiff

**CERTIFICATION PURSUANT
TO FEDERAL SECURITIES LAWS**

1. I, Ronald A. Schoen, make this declaration pursuant to Section 27(a)(2) of the Securities Act of 1933 (“Securities Act”) and/or Section 21D(a)(2) of the Securities Exchange Act of 1934 (“Exchange Act”) as amended by the Private Securities Litigation Reform Act of 1995.

2. I have reviewed a Complaint against Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) and authorize the filing of a comparable complaint on my behalf.

3. I did not purchase or acquire Eiger securities at the direction of plaintiffs’ counsel or in order to participate in any private action arising under the Securities Act or Exchange Act.

4. I am willing to serve as a representative party on behalf of a Class of investors who purchased or otherwise acquired Eiger securities during the class period, including providing testimony at deposition and trial, if necessary. I understand that the Court has the authority to select the most adequate lead plaintiff in this action.

5. The attached sheet lists all of my transactions in Eiger securities during the Class Period as specified in the Complaint.

6. During the three-year period preceding the date on which this Certification is signed, I have not served or sought to serve as a representative party on behalf of a class under the federal securities laws.

7. I agree not to accept any payment for serving as a representative party on behalf of the class as set forth in the Complaint, beyond my pro rata share of any recovery, except such reasonable costs and expenses directly relating to the representation of the class as ordered or approved by the Court.

8. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed 10/19/2022
(Date)

DocuSigned by:

Ronald A. Schoen

(Signature)
8781470FB4C5C4E0...

Ronald A. Schoen

(Type or Print Name)

Eiger BioPharmaceuticals, Inc. (EIGR)

Ronald A. Schoen

List of Purchases and Sales

Transaction Type	Security Type	Date	Number of Shares/Unit	Price Per Share/Unit
Purchase	Common Stock	3/24/2021	3	\$8.3700
Purchase	Common Stock	3/24/2021	97	\$8.3700
Purchase	Common Stock	3/24/2021	100	\$8.3800
Purchase	Common Stock	3/24/2021	100	\$8.4800
Purchase	Common Stock	4/7/2021	100	\$8.2400
Purchase	Common Stock	4/12/2021	32	\$8.1000
Purchase	Common Stock	4/12/2021	68	\$8.1000
Purchase	Common Stock	4/12/2021	100	\$8.1200
Purchase	Common Stock	4/12/2021	100	\$8.1300
Purchase	Common Stock	4/12/2021	100	\$8.1400
Purchase	Common Stock	4/23/2021	60	\$8.2700
Purchase	Common Stock	4/23/2021	40	\$8.2700
Purchase	Common Stock	6/2/2021	49	\$7.8500
Purchase	Common Stock	6/2/2021	51	\$7.8500
Purchase	Common Stock	6/2/2021	100	\$7.8600
Purchase	Common Stock	6/21/2021	10	\$7.8700
Purchase	Common Stock	6/21/2021	9	\$7.9200
Purchase	Common Stock	6/21/2021	1	\$7.9200
Purchase	Common Stock	6/22/2021	9	\$7.7400
Purchase	Common Stock	6/22/2021	1	\$7.7400
Purchase	Common Stock	6/22/2021	10	\$7.7500
Purchase	Common Stock	6/22/2021	10	\$7.7500
Purchase	Common Stock	6/22/2021	9	\$7.7600
Purchase	Common Stock	6/22/2021	1	\$7.7600
Purchase	Common Stock	6/22/2021	10	\$7.7800
Purchase	Common Stock	7/15/2021	99	\$7.8600
Purchase	Common Stock	7/15/2021	1	\$7.8600
Purchase	Common Stock	7/15/2021	33	\$7.9200
Purchase	Common Stock	7/15/2021	67	\$7.9200
Purchase	Common Stock	7/15/2021	69	\$7.9400
Purchase	Common Stock	7/15/2021	1	\$7.9400
Purchase	Common Stock	7/15/2021	30	\$7.9400
Purchase	Common Stock	7/15/2021	100	\$7.9600
Purchase	Common Stock	7/27/2021	100	\$7.8500
Purchase	Common Stock	7/30/2021	98	\$7.8300
Purchase	Common Stock	7/30/2021	2	\$7.8300
Purchase	Common Stock	8/19/2021	37	\$7.6500
Purchase	Common Stock	8/19/2021	2	\$7.6500
Purchase	Common Stock	8/19/2021	61	\$7.6500
Purchase	Common Stock	8/19/2021	100	\$7.6700
Purchase	Common Stock	8/19/2021	89	\$7.6900
Purchase	Common Stock	8/19/2021	11	\$7.6900
Purchase	Common Stock	8/19/2021	100	\$7.7000
Purchase	Common Stock	8/19/2021	100	\$7.7100
Purchase	Common Stock	8/26/2021	80	\$7.8200
Purchase	Common Stock	8/26/2021	20	\$7.8200
Purchase	Common Stock	8/26/2021	3	\$7.8600
Purchase	Common Stock	8/26/2021	33	\$7.8600
Purchase	Common Stock	8/26/2021	36	\$7.8600
Purchase	Common Stock	8/26/2021	28	\$7.8600
Purchase	Common Stock	8/26/2021	100	\$7.8600
Purchase	Common Stock	8/30/2021	100	\$8.0000
Purchase	Common Stock	9/7/2021	100	\$7.8500
Purchase	Common Stock	9/8/2021	8	\$7.8000
Purchase	Common Stock	9/8/2021	2	\$7.8000
Purchase	Common Stock	9/8/2021	10	\$7.8100
Purchase	Common Stock	9/8/2021	8	\$7.8200
Purchase	Common Stock	9/8/2021	2	\$7.8200
Purchase	Common Stock	9/8/2021	8	\$7.8300
Purchase	Common Stock	9/8/2021	1	\$7.8300

Eiger BioPharmaceuticals, Inc. (EIGR)

Ronald A. Schoen

List of Purchases and Sales

Transaction Type	Security Type	Date	Number of Shares/Unit	Price Per Share/Unit
Purchase	Common Stock	9/8/2021	1	\$7.8300
Purchase	Common Stock	9/8/2021	10	\$7.8400
Purchase	Common Stock	9/9/2021	10	\$7.7200
Purchase	Common Stock	9/9/2021	10	\$7.7400
Purchase	Common Stock	9/9/2021	10	\$7.7500
Purchase	Common Stock	9/9/2021	10	\$7.7500
Purchase	Common Stock	9/9/2021	10	\$7.7600
Purchase	Common Stock	9/9/2021	9	\$7.7800
Purchase	Common Stock	9/9/2021	10	\$7.7700
Purchase	Common Stock	9/9/2021	1	\$7.7800
Purchase	Common Stock	9/9/2021	10	\$7.7900
Purchase	Common Stock	9/9/2021	10	\$7.8000
Purchase	Common Stock	9/10/2021	10	\$7.4900
Purchase	Common Stock	9/10/2021	10	\$7.5000
Purchase	Common Stock	9/10/2021	10	\$7.5200
Purchase	Common Stock	9/10/2021	1	\$7.5200
Purchase	Common Stock	9/10/2021	9	\$7.5200
Purchase	Common Stock	9/10/2021	9	\$7.5300
Purchase	Common Stock	9/10/2021	1	\$7.5300
Purchase	Common Stock	9/10/2021	9	\$7.5400
Purchase	Common Stock	9/10/2021	1	\$7.5400
Purchase	Common Stock	9/10/2021	9	\$7.5500
Purchase	Common Stock	9/10/2021	1	\$7.5500
Purchase	Common Stock	9/10/2021	10	\$7.6000
Purchase	Common Stock	9/10/2021	10	\$7.6200
Purchase	Common Stock	9/10/2021	10	\$7.6300
Purchase	Common Stock	9/10/2021	10	\$7.6300
Purchase	Common Stock	9/10/2021	2	\$7.6400
Purchase	Common Stock	9/10/2021	1	\$7.6400
Purchase	Common Stock	9/10/2021	6	\$7.6400
Purchase	Common Stock	9/10/2021	1	\$7.6400
Purchase	Common Stock	9/10/2021	9	\$7.6300
Purchase	Common Stock	9/10/2021	1	\$7.6300
Purchase	Common Stock	9/17/2021	100	\$7.0600
Purchase	Common Stock	9/17/2021	10	\$7.0700
Purchase	Common Stock	9/17/2021	100	\$7.0800
Purchase	Common Stock	9/17/2021	60	\$7.0800
Purchase	Common Stock	9/17/2021	40	\$7.0800
Purchase	Common Stock	9/30/2021	36	\$6.6900
Purchase	Common Stock	9/30/2021	64	\$6.6900
Purchase	Common Stock	9/30/2021	10	\$6.7000
Purchase	Common Stock	9/30/2021	10	\$6.7100
Purchase	Common Stock	10/4/2021	10	\$6.4700
Purchase	Common Stock	10/4/2021	9	\$6.5100
Purchase	Common Stock	10/4/2021	1	\$6.5100
Purchase	Common Stock	10/7/2021	10	\$6.3400
Purchase	Common Stock	10/7/2021	10	\$6.3700
Purchase	Common Stock	10/7/2021	6	\$6.3600
Purchase	Common Stock	10/7/2021	4	\$6.3600
Purchase	Common Stock	10/7/2021	10	\$6.3700
Purchase	Common Stock	10/7/2021	10	\$6.3700
Purchase	Common Stock	10/7/2021	9	\$6.3500
Purchase	Common Stock	10/7/2021	1	\$6.3500
Purchase	Common Stock	10/26/2021	9	\$6.3000
Purchase	Common Stock	10/26/2021	1	\$6.3000
Purchase	Common Stock	10/26/2021	17	\$6.3100
Purchase	Common Stock	10/26/2021	1	\$6.3100
Purchase	Common Stock	10/26/2021	1	\$6.3100
Purchase	Common Stock	10/26/2021	10	\$6.3200
Purchase	Common Stock	10/27/2021	9	\$5.9600

Eiger BioPharmaceuticals, Inc. (EIGR)

Ronald A. Schoen

List of Purchases and Sales

Transaction Type	Security Type	Date	Number of Shares/Unit	Price Per Share/Unit
Sale	Common Stock	8/31/2021	(1)	\$8.1400
Sale	Common Stock	8/31/2021	(1)	\$8.1400
Sale	Common Stock	8/31/2021	(4)	\$8.1400
Sale	Common Stock	8/31/2021	(1)	\$8.1400
Sale	Common Stock	8/31/2021	(5)	\$8.1400
Sale	Common Stock	8/31/2021	(1)	\$8.1400
Sale	Common Stock	8/31/2021	(1)	\$8.1400
Sale	Common Stock	9/13/2021	(69)	\$7.7000
Sale	Common Stock	9/13/2021	(1)	\$7.7000
Sale	Common Stock	9/21/2021	(100)	\$7.1000
Sale	Common Stock	9/22/2021	(10)	\$7.2300
Sale	Common Stock	9/23/2021	(200)	\$7.3100
Sale	Common Stock	10/4/2021	(16)	\$6.6500
Sale	Common Stock	10/4/2021	(4)	\$6.6500
Sale	Common Stock	10/8/2021	(59)	\$6.4000
Sale	Common Stock	10/8/2021	(1)	\$6.4000
Sale	Common Stock	10/21/2021	(1)	\$6.8400
Sale	Common Stock	10/28/2021	(45)	\$6.8600
Sale	Common Stock	10/28/2021	(5)	\$6.8600
Sale	Common Stock	10/28/2021	(45)	\$6.8100
Sale	Common Stock	10/28/2021	(5)	\$6.8100
Sale	Common Stock	11/1/2021	(14)	\$6.9900
Sale	Common Stock	11/1/2021	(86)	\$6.9900
Sale	Common Stock	11/3/2021	(50)	\$7.8400
Sale	Common Stock	11/3/2021	(76)	\$7.8100
Sale	Common Stock	11/3/2021	(24)	\$7.8100
Sale	Common Stock	11/4/2021	(50)	\$7.9700
Sale	Common Stock	11/30/2021	(100)	\$6.0600
Sale	C 20221021 7.5	3/15/2022	(1)	\$1.0000
Sale	C 20230120 12.5	8/22/2022	(11)	\$2.0000

CIVIL COVER SHEET

The JS-CAND 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved in its original form by the Judicial Conference of the United States in September 1974, is required for the Clerk of Court to initiate the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

RONALD A. SCHOEN, Individually and on Behalf of All Others Similarly Situated

(b) County of Residence of First Listed Plaintiff Los Angeles County, California (EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)

Jennifer Pafiti, Pomerantz LLP, 1100 Glendon Avenue, 15th Floor Los Angeles, California 90024, T.: (310) 405-7190

DEFENDANTS

EIGER BIOPHARMACEUTICALS, INC., DAVID A. CORY, and SRIRAM RYALI

County of Residence of First Listed Defendant Santa Clara County, California (IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- 1 U.S. Government Plaintiff
2 U.S. Government Defendant
3 Federal Question (U.S. Government Not a Party)
4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

Table with columns for Plaintiff (PTF) and Defendant (DEF) citizenship: Citizen of This State, Citizen of Another State, Citizen or Subject of a Foreign Country, Incorporated or Principal Place of Business In This State, Incorporated and Principal Place of Business In Another State, Foreign Nation.

IV. NATURE OF SUIT (Place an "X" in One Box Only)

Large table with categories: CONTRACT, REAL PROPERTY, TORTS, CIVIL RIGHTS, PRISONER PETITIONS, HABEAS CORPUS, OTHER, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES.

V. ORIGIN (Place an "X" in One Box Only)

- 1 Original Proceeding
2 Removed from State Court
3 Remanded from Appellate Court
4 Reinstated or Reopened
5 Transferred from Another District (specify)
6 Multidistrict Litigation-Transfer
8 Multidistrict Litigation-Direct File

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 15 U.S.C. §§ 78j(b) and 78t(a) and Rule 10b-5 promulgated thereunder by the SEC (17 C.F.R. § 240.10b-5).

Brief description of cause: Violations of the federal securities laws.

VII. REQUESTED IN COMPLAINT:

CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, Fed. R. Civ. P. DEMAND \$

CHECK YES only if demanded in complaint: JURY DEMAND: Yes No

VIII. RELATED CASE(S), IF ANY (See instructions):

JUDGE DOCKET NUMBER

IX. DIVISIONAL ASSIGNMENT (Civil Local Rule 3-2)

(Place an "X" in One Box Only) SAN FRANCISCO/OAKLAND SAN JOSE EUREKA-MCKINLEYVILLE

DATE 11/08/2022

SIGNATURE OF ATTORNEY OF RECORD

/s/ Jennifer Pafiti

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS-CAND 44

Authority For Civil Cover Sheet. The JS-CAND 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved in its original form by the Judicial Conference of the United States in September 1974, is required for the Clerk of Court to initiate the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I. a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the “defendant” is the location of the tract of land involved.)
- c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section “(see attachment).”
- II. Jurisdiction.** The basis of jurisdiction is set forth under Federal Rule of Civil Procedure 8(a), which requires that jurisdictions be shown in pleadings. Place an “X” in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.
- (1) United States plaintiff. Jurisdiction based on 28 USC §§ 1345 and 1348. Suits by agencies and officers of the United States are included here.
 - (2) United States defendant. When the plaintiff is suing the United States, its officers or agencies, place an “X” in this box.
 - (3) Federal question. This refers to suits under 28 USC § 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.
 - (4) Diversity of citizenship. This refers to suits under 28 USC § 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS-CAND 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an “X” in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerk(s) in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.
- V. Origin.** Place an “X” in one of the six boxes.
- (1) Original Proceedings. Cases originating in the United States district courts.
 - (2) Removed from State Court. Proceedings initiated in state courts may be removed to the district courts under Title 28 USC § 1441. When the petition for removal is granted, check this box.
 - (3) Remanded from Appellate Court. Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.
 - (4) Reinstated or Reopened. Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.
 - (5) Transferred from Another District. For cases transferred under Title 28 USC § 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.
 - (6) Multidistrict Litigation Transfer. Check this box when a multidistrict case is transferred into the district under authority of Title 28 USC § 1407. When this box is checked, do not check (5) above.
 - (8) Multidistrict Litigation Direct File. Check this box when a multidistrict litigation case is filed in the same district as the Master MDL docket. Please note that there is no Origin Code 7. Origin Code 7 was used for historical records and is no longer relevant due to changes in statute.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC § 553. Brief Description: Unauthorized reception of cable service.
- VII. Requested in Complaint.** Class Action. Place an “X” in this box if you are filing a class action under Federal Rule of Civil Procedure 23. Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction. Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases.** This section of the JS-CAND 44 is used to identify related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.
- IX. Divisional Assignment.** If the Nature of Suit is under Property Rights or Prisoner Petitions or the matter is a Securities Class Action, leave this section blank. For all other cases, identify the divisional venue according to Civil Local Rule 3-2: “the county in which a substantial part of the events or omissions which give rise to the claim occurred or in which a substantial part of the property that is the subject of the action is situated.”
- Date and Attorney Signature.** Date and sign the civil cover sheet.